All In Biotech

NDA 210361 · Journey

Qbrexza

Glycopyrronium Tosylate · Topical

Last checked: Nov 20, 2026Latest source record: Oct 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jun 28, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

160

72 Phase 3, 12 recruiting

FAERS reports

1,551

788 serious, 99 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 21, 2026.

Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older ( 1 ).

Mechanism: Glycopyrronium is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, glycopyrronium inhibits the action of acetylcholine on sweat glands, reducing sweating.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • QBREXZA · GLYCOPYRRONIUM TOSYLATE EQ 2.4% BASE · CLOTH, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Glycopyrronium" as an intervention, any sponsor and status, largest first.

All 160 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • mydriasis273
  • dry mouth241
  • off label use195
  • vision blurred188
  • drug ineffective97
  • intentional product misuse94
  • urinary retention89
  • headache85
  • constipation72
  • dyspnoea69
  • pneumonia59
  • nausea54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20083
20093
20103
20112
20125
20136
20148
201517
201637
201739
201857
2019491
2020226
2021170
202289
2023106
2024121
2025103
202665

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qbrexza (Glycopyrronium Tosylate)

2024 spending

$2.0M

Beneficiaries

947

2,848 claims

Per beneficiary

$2,159

$21.13 per unit

View as table
YearSpending
2020$0
2021$0
2022$939,657
2023$1,842,539
2024$2,044,939

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 238 on PubMed

Sponsor: Journey

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.